Global Long-acting PrEP Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Long-acting PrEP market size was valued at US$ 321 million in 2025 and is forecast to a readjusted size of US$ 836 million by 2032 with a CAGR of 14.7% during review period.
Long-acting PrEP refers to HIV pre-exposure prophylaxis delivered through formulations or delivery systems that sustain protective drug exposure over extended periods, shifting prevention from daily or event-driven pill-taking to dosing or device replacement at monthly, quarterly, semiannual, or even longer intervals. The primary problem it addresses is the real-world persistence and access gap seen with oral PrEP: many people who would benefit from prevention struggle with continuous daily adherence, timely refills, discreet storage and use, or consistent engagement with care, and fluctuating risk patterns can make stop–start cycles especially prone to protection gaps. By reducing dosing frequency and the day-to-day behavioral burden, long-acting PrEP aims to increase the likelihood of uninterrupted protection while enabling prevention to be packaged more naturally with follow-up, testing, and broader sexual health services. Its product history can be viewed in stages: oral PrEP first established efficacy and became embedded in guidelines and practice; the field then leveraged advances from long-acting HIV treatment—such as micro-/nano-crystal depot technologies, stable injectable formulations, aseptic manufacturing, and cold-chain logistics—to enable the first wave of long-acting PrEP commercialization; and current development is focused on extending duration and diversifying modalities, including longer-interval small-molecule injections, controlled-release implants, and biologics-based approaches with the potential for even less frequent administration. Upstream, long-acting PrEP depends on both conventional pharmaceutical inputs and a more demanding formulation-and-device supply chain: APIs and key intermediates; chemical reagents, catalysts, and solvents; injection- or implant-grade excipients (surfactants, stabilizers, buffers, water for injection, and medical-grade polymers); and the components and consumables required for aseptic production and delivery (injectable-grade glass containers, elastomer stoppers/plungers, seals, needles and safety injection devices, prefilled systems, sterilizing filters, single-use tubing and filling sets, labels, and cold-chain packaging), supported by specialized suppliers providing aseptic fill-finish, sterilization validation, temperature-controlled transport, and quality-system services.In 2025, the global production capacity of long-acting PrEP reached 150,000 doses, while total sales amounted to 117,200 doses. The average selling price was USD 2,660 per dose, and manufacturers’ gross margins ranged between 60% and 70%.
The current long-acting PrEP market is characterized by rising awareness and uneven delivery capacity. Clinical and public health stakeholders increasingly view long-acting options as essential for reaching people who struggle with persistence on oral regimens, yet uptake is often constrained by the practical realities of care delivery—reliable follow-up pathways, standardized testing and risk assessment, trained personnel, and tighter inventory and cold-chain discipline. Differences across countries and regions in reimbursement design, provider networks, stigma, and access for priority populations create markedly different adoption trajectories. As a result, competition today is as much about building a sustainable service model as it is about the medicine itself: streamlined patient journeys, integration with sexual health services, community-based outreach, and models tailored to younger or highly mobile groups.
Looking forward, the market is likely to evolve through a combination of technology diversification and service decentralization. On the technology side, development efforts are converging on longer dosing intervals, fewer touchpoints with the health system, improved tolerability, and more flexible user options, with multiple modalities advancing in parallel and enabling differentiated product portfolios. In parallel, real-world success will depend increasingly on complementary delivery innovations—risk-stratified follow-up that avoids unnecessary visits, expanded roles for community providers and pharmacies, digital support for continuity, and smoother “start–pause–restart” pathways. The market will also become more segmented, with different prevention packages emerging for different exposure patterns and social contexts, shifting differentiation from efficacy alone toward sustained user experience and system efficiency.
Key drivers include the alignment of public health priorities with user preferences for prevention that is easier to maintain and more discreet, along with steady progress in formulation and manufacturing that supports broader scale-up. Payers and providers also have growing incentives to adopt models that emphasize outcomes and continuity rather than repeated transactional visits. At the same time, barriers remain substantial: reliance on clinical infrastructure can slow decentralization, concerns about long drug “tail,” injection-site effects, and reversibility can deter initiation for some, and stigma and privacy dynamics continue to influence both demand and engagement. Supply-side complexity—aseptic manufacturing, cold-chain logistics, and reliable component availability—adds another layer of fragility. Ultimately, expansion is likely to be strongest where payment policy, delivery networks, and community engagement reinforce one another, enabling long-acting prevention to function as a durable system rather than a standalone intervention.
This report is a detailed and comprehensive analysis for global Long-acting PrEP market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Long-acting PrEP market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Long-acting PrEP market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Long-acting PrEP market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Long-acting PrEP market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Long-acting PrEP
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Long-acting PrEP market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, ViiV Healthcare, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Long-acting PrEP market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Cabotegravir
Lenacapavir
Other
Market segment by Dosing Interval
Short-interval Injections
Monthly Injections
Quarterly Injections
Market segment by Drug Properties
Original Drug
Generic Drug
Market segment by Application
Hospital
Clinic
Other
Major players covered
Gilead Sciences
ViiV Healthcare
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Long-acting PrEP product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Long-acting PrEP, with price, sales quantity, revenue, and global market share of Long-acting PrEP from 2021 to 2026.
Chapter 3, the Long-acting PrEP competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Long-acting PrEP breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Long-acting PrEP market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Long-acting PrEP.
Chapter 14 and 15, to describe Long-acting PrEP sales channel, distributors, customers, research findings and conclusion.